Shared on15 Aug 25
With both the discount rate and revenue growth forecasts holding steady, analyst valuation for DarioHealth remained unchanged, with the consensus price target steady at $1.96. What's in the News Shareholders ratified the appointment of Kesselman & Kesselman (PwC) as independent auditor for 2025.